Biofrontera AG operates as a biopharmaceutical company, which engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products are used for the treatment of chronic, antihistamine refractory urticaria and migraine prophylaxis. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
Company profile
Ticker
BFFTF, BFAGY
Exchange
Website
CEO
Hermann Luebbert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BFFTF stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
14 Mar 22
6-K
Biofrontera files Form 15F to suspend SEC Reporting Requirements and starts trading Level I ADS program on US OTC market
9 Mar 22
15F-12B
Securities registration termination (foreign)
9 Mar 22
POS AM
Prospectus update (post-effective amendment)
9 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Mar 22
25
Voluntary exchange delisting
24 Feb 22
6-K
Current report (foreign)
24 Feb 22
6-K
Current report (foreign)
22 Feb 22
6-K
Current report (foreign)
14 Feb 22
6-K
Current report (foreign)
1 Feb 22
Latest ownership filings
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
25 Feb 22
SC 13G
Biofrontera Inc.
10 Feb 22
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
21 Dec 21
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
29 Nov 21
3
Biofrontera Inc.
28 Oct 21
SC 13D/A
Maruho Co., Ltd.
25 Feb 21
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
27 Nov 20
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
23 Sep 20
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
28 Aug 20
SC 13D/A
DEUTSCHE BALATON AKTIENGESELLSCHAFT
12 Mar 20
Financial summary
Quarter (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
47.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 148.28 mm |
Total shares | 30.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Deutsche Balaton Aktiengesellschaft | 16.99 mm | $62.52 mm |
Maruho | 13.40 mm | $85.76 mm |